PT  - JOURNAL ARTICLE
AU  - Vaughan-Shaw, P.G.
AU  - Grimes, G.
AU  - Blackmur, JP
AU  - Timofeeva, M.
AU  - Walker, M
AU  - Ooi, L.Y
AU  - Svinti, Victoria
AU  - Donnelly, Kevin
AU  - Din, FVN
AU  - Farrington, S.M.
AU  - Dunlop, M.G.
TI  - Oral Vitamin D supplementation induces transcriptomic changes in rectal mucosa that are consistent with anti-tumour effects
AID  - 10.1101/2021.05.04.21255629
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.04.21255629
4099  - http://medrxiv.org/content/early/2021/05/10/2021.05.04.21255629.short
4100  - http://medrxiv.org/content/early/2021/05/10/2021.05.04.21255629.full
AB  - Background Risk for several common cancers is influenced by the transcriptomic landscape of the respective tissue-of-origin. Vitamin D influences in-vitro gene expression and cancer cell growth. We sought to determine whether oral vitamin D induces beneficial gene expression effects in human rectal epithelium and identify biomarkers of response.Methods Blood and rectal mucosa was sampled from 191 human subjects and mucosa gene expression (HT12) correlated with plasma vitamin D (25-OHD) to identify differentially expressed genes. Fifty subjects were then administered 3200IU/day oral vitamin D3 and matched blood/mucosa resampled after 12 weeks’. Transcriptomic changes (HT12/RNAseq) after supplementation were tested against the prioritised genes for gene-set and GO-process enrichment. To identify blood biomarkers of mucosal response, we derived receiver-operator curves and C-statistic (AUC) and tested biomarker reproducibility in an independent Supplementation Trial (BEST-D).Results 629 genes were associated with 25-OHD level (P<0.01), highlighting 453 GO-term processes (FDR<0.05). In the whole intervention cohort, vitamin D supplementation enriched the prioritised mucosal gene-set (upregulated gene-set P<1.0E-07; downregulated gene-set P<2.6E-05) and corresponding GO terms (P=2.90E-02), highlighting gene expression patterns consistent with anti-tumour effects. However, only 9 individual participants (18%) showed a significant response (NM gene-set enrichment P<0.001) to supplementation. Expression changes in HIPK2 and PPP1CC expression served as blood biomarkers of mucosal transcriptomic response (AUC=0.84 [95%CI:0.66-1.00]), and replicated in BEST-D trial subjects (HIPK2 AUC=0.83 [95%CI:0.77-0.89]; PPP1CC AUC=0.91 [95%CI:0.86-0.95]).Conclusions Higher plasma 25-OHD correlates with rectal mucosa gene expression patterns consistent with anti-tumour effects and this beneficial signature is induced by short-term vitamin D supplementation. Heterogenous gene expression responses to vitamin D may limit the ability of randomised trials to identify beneficial effects of supplementation on CRC risk. However, in the current study blood expression changes in HIPK2 and PPP1CC identify those participants with significant anti-tumor transcriptomic responses to supplementation in the rectum. These data provide compelling rationale for a trial of vitamin D and CRC prevention using easily assayed blood gene expression signatures as intermediate biomarkers of response.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov Identifier: NCT04868227Funding StatementGrant Support: The work reported in this manuscript was supported by a Cancer Research UK Programme Grant (C348/A18927) and a Project Leader Grant to MGD (MRC Human Genetics Unit Centre Grant - U127527198). MGD is an MRC Investigator. PVS was supported by a NES SCREDS clinical lectureship, MRC Clinical Research Training Fellowship (MR/M004007/1), a Research Fellowship from the Harold Bridges bequest and by the Melville Trust for the Care and Cure of Cancer. JPB is supported by an ECAT-linked CRUK ECRC Clinical training award (C157/A23218). FVND is supported by a CSO Senior Clinical Fellowship. LYO was supported by a CRUK Research Training Fellowship (C10195/A12996). The work was also supported by the infrastructure and staffing of the Edinburgh CRUK Cancer Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided informed written consent. The research was approved by the South East Scotland Research Ethics Committee 03 (11/SS/0109), South East Scotland Research Ethics Committee 01 (13/SS/0248) and Lothian National Health Service Research and Development office (2014/0058).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAvailable at https://www.ncbi.nlm.nih.gov/geo/ GEO ID GSE157982. Full phenotypic data available from the corresponding author on reasonable request. https://www.ncbi.nlm.nih.gov/geo/ 25-OHD25-hydroxyvitamin DAUCArea under curveBEST-DBiochemical Efficacy and Safety Trial of Vitamin D trialCRCcolorectal cancerDNADeoxyribonucleic acidFCfold-changeGOGene ontologyNMnormal mucosaPBMCperipheral blood mononuclear cellsRCTrandomised control trialRNAribonucleic acidSCOVIDSScottish Vitamin D studySNPsingle nucleotide polymorphismVDRvitamin D receptor gene